STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1/Line 2-3 Page 2/Line 41-49	Title Abstract/Paragraph2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2,Line 41-58	Abstract/Paragraph2-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 2-3,Line 63-95	Introduction/Paragraph1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 3,Line 95-97	Introduction/Paragraph3
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6,Line 198-209 (Key indicators included in the study)	Methods/Paragraph10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 3,Line 102-105 (Recruitment time) Page 6,Line 198-209 (Follow-up time and data collection)	Methods/Paragraph1 Methods/Paragraph10
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 3,Line 102-105 (Participants: 10 patients who received an anatomy-conforming hybrid surgery protocol in our center)	Methods/Paragraph1
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 4-6,Line 127-196 (Describe surgical intervention methods in detail)	Methods/Paragraph2-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6,Line 198-209 (Data sources)	Methods/Paragraph10

Bias	9	Describe any efforts to address potential sources of bias	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Study size	10	Explain how the study size was arrived at	Page 4,Line 102-105 (All 10 cases received this hybrid protocol in the past two years were studied)	Methods/Paragraph1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 7,Line 211-214	Methods/Paragraph11
		(b) Describe any methods used to examine subgroups and interactions	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(c) Explain how missing data were addressed	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(e) Describe any sensitivity analyses	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 3,Line 102-105 Page 7,Line 218 (10 participants were included in the analysis)	Methods/Paragraph1 Results/Paragraph1
		(b) Give reasons for non-participation at each stage	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(c) Consider use of a flow diagram	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 3-4,Line 101-120, Page 17,Table 1	Methods/Paragraph1 *Table 1*
		(b) Indicate number of participants with missing data for each variable of interest	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 6-7,Line 202-204 Page 8,Line 238-239	Methods/Paragraph10 Results/Paragraph2
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 7-8,Line 216-252,259-262 Page 18-19,Table 2	Results/Paragraph1-3 Table *2*
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95%	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)

		confidence interval). Make clear which confounders were adjusted for and why they were included		
		(b) Report category boundaries when continuous variables were categorized	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A(No relevant contents in the study)	N/A(No relevant contents in the study)
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 7-8,Line 216-252 Page 10,Line 304-309 Page 11,Line 350-354	Results/Paragraph1-2 Discussion/Paragraph5 Discussion/Paragraph9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11,Line 354-357	Discussion/Paragraph9

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 8-11,Line 265-340 Page 11,Line 354-357	Discussion/Paragraph1-7 Discussion/Paragraph9
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 9,Line 283-293 Page 11,Line 350-354	Discussion/Paragraph3 Discussion/Paragraph9
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 11,Line 363-365	Acknowledgments

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/apm-21-1569
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copy editing and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.